[미국특허]
Molecular biomarker set for early detection of ovarian cancer
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12Q-001/68
G01N-033/487
G01N-033/50
G01N-033/574
출원번호
US-0734190
(2015-06-09)
등록번호
US-9914974
(2018-03-13)
발명자
/ 주소
Bajic, Vladimir
Kaur, Mandeep
출원인 / 주소
King Abdullah University of Science and Technology
대리인 / 주소
Smith, Gambrell & Russell
인용정보
피인용 횟수 :
0인용 특허 :
74
초록▼
Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify
Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
대표청구항▼
1. A method of identifying an individual to be treated for ovarian cancer, consisting of: a) detecting expression levels of TFAP2A, E2F5, and CA125from a sample obtained from the individual; b) selecting the individual for treatment when expression levels of TFAP2A, E2F5, and CA125 are higher relati
1. A method of identifying an individual to be treated for ovarian cancer, consisting of: a) detecting expression levels of TFAP2A, E2F5, and CA125from a sample obtained from the individual; b) selecting the individual for treatment when expression levels of TFAP2A, E2F5, and CA125 are higher relative to the expression levels of TFAP2A, E2F5, and CA125 from a control; and c) administering to the individual a treatment for ovarian cancer, wherein the treatment for ovarian cancer is selected from the group consisting of surgery, radiation, and chemotherapy. 2. The method of claim 1, wherein the expression levels are determined by protein level or mRNA level of TFAP2A, CA125 and E2F5. 3. The method of claim 2, wherein the protein level of TFAP2A, CA125 and E2F5 is determined with an antibody. 4. The method of claim 2, wherein the mRNA levels of TFAP2A, CA125 and E2F5 from the individual are determined. 5. The method of claim 2, wherein the mRNA level is determined from ovarian tissue or blood from the individual. 6. The method of claim 1, wherein the control is tissue or blood from one or more normal individuals or is from tissue or blood from the individual. 7. The method of claim 1, wherein the method detects the stage of ovarian cancer in the individual. 8. The method of claim 7, wherein the stage is stage IA, IC, IIIC, or a combination thereof. 9. A method of identifying an individual to be treated for ovarian cancer, consisting of: a) detecting expression levels of TFAP2A, E2F5, and CA125 from a sample obtained from the individual; b) selecting the individual for treatment when expression levels of TFAP2A, E2F5, and CA125 are higher relative to the expression levels of TFAP2A, E2F5, and CA125 from a control; c) performing an additional ovarian cancer detection method; and d) administering to the individual a treatment for ovarian cancer, wherein the treatment for ovarian cancer is selected from the group consisting of surgery, radiation, and chemotherapy, and wherein the additional ovarian cancer detection method is selected from the group consisting of palpitation, ultrasound, magnetic resonance imaging, X-ray, CT scan, blood testing, and biopsy. 10. The method of claim 1, wherein the sample is ovarian tissue, blood, serum, or plasma. 11. The method of claim 1, wherein the chemotherapy includes administering a chemotherapeutic agent selected from the group consisting of drugs that contain platinum and taxane compounds. 12. The method of claim 11, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, and paclitaxel. 13. The method of claim 1, wherein chemotherapy comprises administering an effective amount of melphalan, doxorubicin, altretamine, 5-fluorouracil, topotecan, ifosamide, and etoposide.
Glazer Alexander N. ; Mathies Richard A. ; Hung Su-Chun ; Ju Jingyue, Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels.
Babon Jeff,AUX ; Youil Rima,AUX ; Stoerker Jay ; Huff Anne ; Cotton Richard G. H.,AUX, Detection of mismatches by resolvase cleavage using a magnetic bead support.
Brow Mary Ann D. ; Hall Jeff Steven Grotelueschen ; Lyamichev Victor ; Olive David Michael ; Prudent James Robert, Detection of nucleic acid sequences by invader-directed cleavage.
Nadeau James G. ; Pitner J. Bruce ; Schram James L. ; Linn C. Preston ; Vonk Glenn P. ; Walker G. Terrance, Detection of nucleic acids by fluorescence quenching.
Nadeau James G. ; Pitner J. Bruce ; Schram James L. ; Linn C. Preston ; Vonk Glenn P. ; Walker G. Terrance, Detection of nucleic acids by fluorescence quenching.
Whiteley Norman M. (San Carlos CA) Hunkapiller Michael W. (San Carlos CA) Glazer Alexander N. (Orinda CA), Detection of specific sequences in nucleic acids.
Nelson Norman Charles ; Woodhead James Stuart,GBX ; Weeks Ian,GBX ; Cheikh Azzouz Ben, Labeled hybridization assay probes useful for the detection and quantification of multiple nucleic acid sequences.
Cleuziat Philippe,FRX ; Guillou-Bonnici Francoise,FRX ; Mallet Francois,FRX ; Levasseur Pierre,FRX, Method for nucleic acid amplification by transcription using displacement, and reagents and kit therefor.
Mirzabekov Andrei Darievich,RUX ; Lysov Yuri Petrovich,RUX ; Dubley Svetlana A.,RUX, Method for performing site-specific affinity fractionation for use in DNA sequencing.
Wu Linxian ; Coombs Jana ; Malmstrom Sharon L. ; Glass Michael J., Methods and apparatus for preparing, amplifying, and discriminating multiple analytes.
Heller Michael James ; O'Connell James Patrick ; Juncosa Robert David ; Sosnowski Ronald George ; Jackson Thomas Ratcliffe, Methods for hybridization analysis utilizing electrically controlled hybridization.
Sousa Rui ; Jendrisak Jerome J., Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside trip.
Mirzabekov Andrei Darievich,RUX ; Lysov Yuri Petrovich,RUX ; Shick Valentine Vladimirovich ; Dubiley Svetlana Alekseevna,RUX, Microchip method for the enrichment of specific DNA sequences.
Hase Tetsu,JPX ; Masubuchi Harumi,JPX, Nucleic acid detection by repetitive synthesis and degradation of a nucleotide on a nuclease resistant oligonucleotide.
Urdea Michael S. ; Horn Thomas ; Chang Chu-An ; Warner Brian ; Fultz Timothy J., Nucleic acid hybridization assays employing large comb-type branched polynucleotides.
Hollis Mark A. ; Ehrlich Daniel J. ; Murphy R. Allen ; Kosicki Bernard B. ; Rathman Dennis D. ; Mathews Richard H. ; Burke Barry E. ; Eggers Mitch D. ; Hogan Michael E. ; Varma Rajender Singh, Optical and electrical methods and apparatus for molecule detection.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.